JOURNAL
Current Issue
Journal Archive
 

Chief Editor -
Abdulrazak Abyad MD, MPH, MBA, AGSF, AFCHSE

.........................................................

Publisher -
Lesley Pocock
medi+WORLD International
AUSTRALIA
Email
: lesleypocock@mediworld.com.au
publishermwi@gmail.com
.........................................................

Editorial Enquiries -
abyad@cyberia.net.lb
.........................................................

Advertising Enquiries -
lesleypocock@mediworld.com.au
.........................................................

While all efforts have been made to ensure the accuracy of the information in this journal, opinions expressed are those of the authors and do not necessarily reflect the views of The Publishers, Editor or the Editorial Board. The publishers, Editor and Editorial Board cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; or the views and opinions expressed. Publication of any advertisements does not constitute any endorsement by the Publishers and Editors of the product advertised.

The contents of this journal are copyright. Apart from any fair dealing for purposes of private study, research, criticism or review, as permitted under the Australian Copyright Act, no part of this program may be reproduced without the permission of the publisher.

WFM / MEJFM November 2024

Metformin in the treatment of chronic obstructive pulmonary disease even in cases with normal weight


Mehmet Rami Helvaci (1), Tulin Serap Yilmaz (2), Hulya Halici (3), Alper Sevinc (1), Celaletdin Camci (1), Abdulrazak Abyad (4), Lesley Pocock (5)

(1) Specialist of Internal Medicine, MD, Turkey
(2) Department of Emergency Medicine, MD, Turkey
(3) Manager of Writing and Statistics, Turkey
(4) Middle-East Academy for Medicine of Aging, MD, Lebanon
(5) medi-WORLD International, Australia

Corresponding author:
Address of Correspondence
Prof Dr Mehmet Rami Helvaci
07400, ALANYA, Turkey
Phone: 00-90-506-4708759
Email: mramihelvaci@hotmail.com

Received: September 2024. Accepted: October 2024; Published: November 1, 2024.Citation: Helvaci MR et al. Metformin in the treatment of chronic obstructive pulmonary disease even in cases with normal weight. World Family Medicine. November 2024; 22(10): 21-35. DOI: 10.5742/MEWFM.2024.95257842


Abstract


Background: Hardened red blood cells (RBC)-induced capillary endothelial damage initiates at birth, and terminates with atherosclerotic end-organ insufficiencies in early years of life in the sickle cell diseases (SCD).

Methods: All patients with the SCD were studied.

Results: We included 222 males and 212 females with similar mean ages (30.8 vs 30.3 years, p>0.05, respectively). Smoking (23.8% vs 6.1%, p<0.001), alcohol (4.9% vs 0.4%, p<0.001), transfused RBC in their lives (48.1 vs 28.5 units, p=0.000), disseminated teeth losses (5.4% vs 1.4%, p<0.001), ileus (7.2% vs 1.4%, p<0.001), chronic obstructive pulmonary disease (COPD) (25.2% vs 7.0%, p<0.001), cirrhosis (8.1% vs 1.8%, p<0.001), leg ulcers (19.8% vs 7.0%, p<0.001), digital clubbing (14.8% vs 6.6%, p<0.001), coronary heart disease (18.0% vs 13.2%, p<0.05), chronic renal disease (9.9% vs 6.1%, p<0.05), and stroke (12.1% vs 7.5%, p<0.05) were all higher in males, significantly.

Conclusion: SCD are prototypes of an accelerated atherosclerotic process all over the body. On the other hand, the role of excess fat tissue on the systemic atherosclerosis, the efficacy of metformin in loss of appetite, and atherosclerotic background of COPD are obvious in the literature. Since metformin is a safe, cheap, oral, long term used, and effective drug for the treatment of excess weight, it should be prescribed in COPD even in patients with the normal weight to minimise the adverse effects of excess fat tissue on the lungs since there are approximately 20 kg of excess fat tissue between the upper and lower borders of the normal weight in adults.

Key words: Sickle cell diseases, chronic obstructive pulmonary disease, smoking, excess fat tissue, vascular endothelial inflammation,
systemic atherosclerosis, end-organ insufficiency






.................................................................................................................

I About MEJFM I Journal I Advertising I Author Info I Editorial Board I Resources I Contact us I Journal Archive I MEPRCN I Noticeboard I News and Updates
Disclaimer - ISSN 148-4196 - © Copyright 2007 medi+WORLD International Pty. Ltd. - All rights reserved